Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 50 years’ experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries.
Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing services.
At Sterling we believe that whilst science can be complex, partnerships should be simple. That’s why we have redefined the CDMO experience with a partnership centred approach marked by transparency, collaboration and trust; a Partnership Development and Manufacturing Organisation (PDMO).
Sterling has five facilities employing more than 1,300 people: its HQ in Dudley, Northumberland, UK and a facility in Ringaskiddy, Ireland, Europe; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin.
6 Apr 2021
Sterling Pharma Solutions acquires ADC Bio
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology (ADC Bio), a UK based bioconjugation development services business specialising in antibody drug conjugates (ADCs). This follows an announcement by Sterling in December…
Cramlington-headquartered pharmaceutical development and manufacturing company, Sterling Pharma Solutions, has announced its acquisition of a facility in Germantown, Wisconsin, US. The facility will further bolster the company’s US presence and will allow Sterling to continue to meet growing customer demand…